Efficacy

In pediatric patients with newly diagnosed AML, the addition of MYLOTARG increased median event-free survival (EFS) vs chemotherapy alone1
16% reduction in the risk of induction failure, relapse, or death with the addition of MYLOTARG vs chemotherapy alone
  • Estimated percentage of patients free of induction failure, relapse, or death at 5 years was 48% (95% CI: 43%-52%) in the MYLOTARG plus chemotherapy arm vs 40% (95% CI: 36%-45%) in the chemotherapy alone arm
  • No difference between treatment arms in overall survival was demonstrated
  • EFS was defined as time from the date of study entry until induction failure, relapse, or death by any cause
  • Induction failure was defined as failure to achieve a complete response (CR) by the end of Induction 2 period
HR=hazard ratio.
REFERENCE
1. MYLOTARG Prescribing Information. New York, NY: Pfizer Inc.